In a blow for HIV prevention, a vaginal gel that showed some effect against HIV in an earlier trial has failed to protect women in a big follow-up trial.
There was no difference in HIV infection rates between the women who got the gel containing the antiretroviral (ARV), tenofovir, and those who got plain gel in the Phase Three trial involving over 2000 women.
...
AllAfrica Subscription Content
You must be an allAfrica.com subscriber for full access to certain content.
You have selected an article from the AllAfrica archive, which requires a subscription. You can subscribe by visiting our subscription page. Or for more information about becoming a subscriber, you can read our subscription and contribution overview.
For information about our premium subscription services:
You can also freely access - without a subscription - hundreds of today's top Africa stories and thousands of recent news articles from our home page »
Already a subscriber? Sign in for full access to article